GlassScriptPhysician profile
Ancil A Jones
NPI 1427024439
$6,967.42
in general payments reported to CMS, 2019-2025
30 companies · $549 in 2025
The $549 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,491 · 2020: $336 · 2021: $875 · 2022: $1,419 · 2023: $1,356 · 2024: $941 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,103.35 | 2019-2024 | Xarelto |
| Abiomed | $862.20 | 2019-2025 | Impella |
| Amgen INC. | $797.15 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $740.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $732.28 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $422.60 | 2019-2025 | Ingevity+, Varithena Administration Pack, Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $342.81 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.95 | 2019-2024 | Lifevest |
| Abbott Laboratories | $302.00 | 2019-2024 | Jeti, Mitraclip, Xience Skypoint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.84 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $192.91 | 2021-2023 | Brilinta |
| Medtronic, INC. | $163.72 | 2021-2024 | Primo Mri Dr Surescan, Hawkone, Reveal Linq |
| Novo Nordisk INC | $115.19 | 2025 | Wegovy |
| Chiesi USA, INC. | $94.40 | 2020-2023 | Cleviprex |
| Regeneron Healthcare Solutions, INC. | $79.33 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $69.11 | 2019 | |
| Scpharmaceuticals INC. | $45.69 | 2025 | |
| Impulse Dynamics (USA) INC. | $42.15 | 2024 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $35.56 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $32.38 | 2025 | Nexletol |
| Terumo Medical Corporation | $28.57 | 2020-2023 | Metacross Otw |
| Inspire Medical Systems, INC. | $26.31 | 2024 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $24.57 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $23.65 | 2019 | |
| Biosense Webster, INC. | $20.73 | 2021 | |
| Daiichi Sankyo INC. | $19.30 | 2025 | Injectafer |
| Biotronik INC. | $17.11 | 2022 | |
| Kci USA, INC. | $16.26 | 2021 | |
| Amarin Pharma, INC. | $13.95 | 2019 | |
| Angiodynamics, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ancil Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.